CRM Research Update — April 20, 2026
Updated Thesis
Salesforce, Inc. is a leading enterprise software company specializing in cloud-based customer relationship management and enterprise applications. The company benefits from a durable competitive moat anchored by pioneering SaaS delivery, a large and growing customer base, and a diversified revenue mix with Service Cloud as the largest segment generating $9.05 billion in FY2025.
The investment grade as of this refresh is B — solid business quality. High-tier business, cheap valuation with 200% upside to fair value
Key Metrics at a Glance
- Revenue growth: +12.1% year over year
- Net margin: 18.0%
- Forward P/E: 22.8x
- Fair value upside: +200.4% to our estimate of $547
Current price: $182.14
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Salesforce, Inc. remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full CRM research →](/stocks/CRM)